Abstract
Primary pleural angiosarcoma (PPA) is a rare and clinically fatal pleural tumor originating from vascular endothelial cells. Herein, we presented the case of a 73-year-old man who was referred to our emergency room with complaints of right chest and back pain for a few days. Chest computed tomography revealed massive pleural effusion and a large mass in the right chest cavity. Thoracoscopic examination demonstrated a large hemorrhagic tumor on the parietal pleura whose pathological analysis indicated PPA. The patient received immunotherapy combined with nivolumab and ipilimumab. A cycle of nivolumab and ipilimumab improved his hemorrhagic anemia and reduced the pleural effusion and tumor size. This treatment outcome suggests that nivolumab and ipilimumab comprise a vital treatment option for PPA.
© 2023 The Author(s). Published by S. Karger AG, Basel
References
Young RJ, Brown NJ, Reed MW, Hughes D, Woll PJ. Angiosarcoma. Lancet Oncol. 2010 Oct;11(10):983–91.
Sedhai YR, Basnyat S, Golamari R, Koirala A, Yuan M. Primary pleural angiosarcoma: case report and literature review. SAGE Open Med Case Rep. 2020;8:2050313X20904595.
Wang X, Lu Z, Luo Y, Cai J, Wei J, Liu A, et al. Characteristics and outcomes of primary pleural angiosarcoma: a retrospective study of 43 published cases. Medicine. 2022;101(6):e28785.
Fata F, O’Reilly E, Ilson D, Pfister D, Leffel D, Kelsen DP, et al. Paclitaxel in the treatment of patients with angiosarcoma of the scalp or face. Cancer. 1999 Nov;86(10):2034–7.
Nagano T, Yamada Y, Ikeda T, Kanki H, Kamo T, Nishigori C. Docetaxel: a therapeutic option in the treatment of cutaneous angiosarcoma: report of 9 patients. Cancer. 2007 Aug;110(3):648–51.
Schlemmer M, Reichardt P, Verweij J, Hartmann JT, Judson I, Thyss A, et al. Paclitaxel in patients with advanced angiosarcomas of soft tissue: a retrospective study of the EORTC soft tissue and bone sarcoma group. Eur J Cancer. 2008 Nov;44(16):2433–6.
Penel N, Bui BN, Bay J-O, Cupissol D, Ray-Coquard I, Piperno-Neumann S, et al. Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX study. J Clin Oncol. 2008 Nov;26(32):5269–74.
Hara N, Fujimoto N, Miyamoto Y, Yamagishi T, Asano M, Fuchimoto Y, et al. Angiosarcoma of the thoracic wall responded well to nanoparticle albumin-bound paclitaxel: a case report. Drug Discov Ther. 2016;10(2):114–6.
Wagner MJ, Othus M, Patel SP, Ryan C, Sangal A, Powers B, et al. Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART). J Immunother Cancer. 2021 Aug;9(8):e002990.
Sindhu S, Gimber LH, Cranmer L, McBride A, Kraft AS. Angiosarcoma treated successfully with anti-PD-1 therapy: a case report. J Immunother Cancer. 2017 Jul 18;5(1):58.
Florou V, Rosenberg AE, Wieder E, Komanduri KV, Kolonias D, Uduman M, et al. Angiosarcoma patients treated with immune checkpoint inhibitors: a case series of seven patients from a single institution. J Immunother Cancer. 2019 Aug 8;7(1):213.
Taube JM, Klein A, Brahmer JR, Xu H, Pan X, Kim JH, et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res. 2014 Oct 1;20(19):5064–74.
Wang X, Wei J, Zeng Z, Cai J, Lu Z, Liu A. Primary pleural epithelioid angiosarcoma treated successfully with anti-PD-1 therapy: a rare case report. Medicine. 2021 Sep;100(35):e27132.
Masson R, Manthripragada G, Liu R, Tavakoli J, Mok K. Possible precipitation of acute coronary syndrome with immune checkpoint blockade: a case report. Perm J. 2020;24:1.
Author Contacts
Kaoru Watanabe, kaowatanabe-nii@umin.ac.jp
Article / Publication Details
Received: November 09, 2022
Accepted: January 20, 2023
Published online: February 17, 2023
Issue release date: January – December
Number of Print Pages: 7
Number of Figures: 3
Number of Tables: 0
eISSN: 1662-6575 (Online)
For additional information: https://www.karger.com/CRO
Open Access License / Drug Dosage / Disclaimer
This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC). Usage and distribution for commercial purposes requires written permission. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
留言 (0)